Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03304548 · ClinicalTrials.gov registry record
Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects
A clinical trial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 10
- Enrollment target
NCT03304548 is a clinical trial that has completed, run by GlaxoSmithKline. The registered enrollment target is 10 participants.
The verdict
NCT03304548 has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
GlaxoSmithKline (GSK) is embarking on a clinical program to assess the treatment of PAH with an Angiotensin converting enzyme 2 (ACE2). This new treatment may require subcutaneous administration, in comparison to current treatments which are taken orally. Hence, GSK would like to conduct this qualitative interview study with PAH subjects to explore subject's perspective and preferences for various modes of treatment administration (daily or weekly subcutaneous injection versus current treatment options). This will be a qualitative study comprising the conduct of semi-structured telephone concept elicitation interviews with 8 to 10 PAH subjects (each approximately 30 minutes in duration) in the United States (US).
Interventions
- OTHER Telephone concept elicitation interview
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-11-22 |
| Est. Completion | 2018-04-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03304548
The ClinicalTrials.gov registry entry for NCT03304548 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Telephone concept elicitation interview is the first listed.
NCT03304548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03304548 about?
NCT03304548 is a clinical study titled "Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects". GlaxoSmithKline (GSK) is embarking on a clinical program to assess the treatment of PAH with an Angiotensin converting enzyme 2 (ACE2). This new treatment may require subcutaneous administration, in comparison to current treatments which are taken orally. Hence, GSK would like to conduct this qualit...
What is the current status of trial NCT03304548?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2017-11-22. Estimated completion is 2018-04-10.
What interventions are being tested in trial NCT03304548?
The interventions under investigation include: Telephone concept elicitation interview (OTHER).
Who is sponsoring clinical trial NCT03304548?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.